Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Specific information collected within each domain of interest

From: Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing’s syndrome

Domains Information collected within each domain
Study design Study design; investigational interventions; study endpoints; inclusion criteria; exclusion criteria
Patient characteristics Number of participants at baseline; main intervention; diagnosis; surgery
Treatment Main intervention; dosage of medications; frequency of taking medications; treatment duration
Outcomes Cushing QoL; Tuebingen CD-25; other HRQL measures utilized in the study; HRQOL factors; HRQL results; survival (number of patients who died during the study), response (how patients responded to treatment); healthcare utilization (length of hospital stays, visits to emergency room, unplanned medical visits)
PRO measures PRO purpose; PRO administration (how it was used to collect patient data); PRO scoring; PRO factors (clinical areas assessed by the measure); PRO primary citation (original authors of the measure); reliability/validity of the PRO measure; number of items in the measure; limitations of the PRO measure; HRQL change (improvements or declines in functioning that was assessed using the measure); HRQL response change (external or environmental factors that impacts the patient’s HRQL); recommendations (comments on the usefulness of the measure)
  1. PRO Patient-Reported Outcome, HRQL Health-Related Quality of Life; CushingQOL and Tuebingen CD-25 are PRO used in Cushing Syndrome